GlassScriptPhysician profile
Natalie Rabb
NPI 1154778561
$6,446.91
in general payments reported to CMS, 2019-2025
52 companies · $3,675 in 2025
The $3,675 reported for 2025 was more than what 98% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $1,470 · 2024: $1,301 · 2025: $3,675.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,978 · Long Term Medical Supply Or Device Loan: $469.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,977.91 |
| Long Term Medical Supply Or Device Loan | $469.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viiv Healthcare Company | $993.82 | 2023-2024 | Dovato, Apretude, Cabenuva |
| Eko Health, INC. | $469.00 | 2025 | |
| Merck Sharp & Dohme LLC | $441.10 | 2023-2025 | Keytruda, Delstrigo, Pifeltro |
| Janssen Biotech, INC. | $349.96 | 2023-2025 | Symtuza, Balversa, Erleada |
| Novartis Pharmaceuticals Corporation | $313.47 | 2024-2025 | |
| Gilead Sciences, INC. | $296.05 | 2023-2024 | |
| Astrazeneca Pharmaceuticals LP | $271.27 | 2023-2025 | Calquence, Breztri, Tagrisso |
| Pfizer INC. | $261.77 | 2023-2025 | |
| Emd Serono, INC. | $237.16 | 2023-2025 | Serostim |
| Lilly USA, LLC | $203.07 | 2024-2025 | Jaypirca, Verzenio, Zepbound |
| Daiichi Sankyo INC. | $168.95 | 2024-2025 | Enhertu, Datroway |
| Takeda Pharmaceuticals U.S.A., INC. | $164.64 | 2024-2025 | Ninlaro, Fruzaqla, Vonvendi |
| E.R. Squibb & Sons, L.L.C. | $152.89 | 2025 | Opdivo |
| Celgene Corporation | $139.30 | 2025 | Reblozyl, Opdivo |
| Genentech USA, INC. | $137.12 | 2025 | Polivy, Phesgo, Tecentriq |
Show all 52 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Natalie Rabb listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.